Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Brahms claims licensing first for prenatal marker:

This article was originally published in Clinica

Executive Summary

German firm Brahms says it has become the first company to license the use of the marker free beta human chorionic gonadotrophin (free betahCG) for prenatal diagnostics. The Hennigsdorf (Berlin) company has signed a licence agreement with JN Macri Technologies, an affiliate of NTD laboratories, New York. Free betahCG is one of several prenatal markers available on Brahms' fully automatic laboratory analyser, Kryptor. The licence agreement strengthens Brahms market position in this segment. Free betahCG is patented for application as a biomarker for assessing risk for foetal anomalies during early pregnancy. Brahms also provides immunoassays for other disease areas, including for the diagnosis of sepsis and infections, thyroid diseases, cancer and cardiac disease.

You may also be interested in...



What Lies Ahead: COVID-19 Vaccination Challenges

The director of adult immunizations at Johns Hopkins International Vaccine Access Center talks to Scrip about undertaking a massive COVID-19 vaccination effort in the US.

P&G: Sales Growth Strongest When Rising Tide Floats All Competitors Across All Categories

P&G’s oral care business drove 35% of total category market growth in the firm’s fiscal 2020 and exemplifies its growth strategy for all segments – grow entire categories rather than take competitors’ market share, says CFO Jon Moeller.

COVID-19 Vaccine 'Brexit Bonus' A Myth

The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.

Topics

UsernamePublicRestriction

Register

OM013133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel